Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program.

Diabetes, Obesity & Metabolism
David R MatthewsBruce Neal

Abstract

This study compared initiation of insulin and other antihyperglycaemic agents (AHAs) with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. After 1 year, fewer participants treated with canagliflozin versus placebo initiated any AHA (7% vs. 16%), insulin (3% vs. 9%) or any non-insulin AHA (5% vs. 12%) (P < .001 for all); overall AHA initiation rates increased over time but were consistently lower with canagliflozin compared with placebo. During the study, the likelihood of initiating insulin was 2.7 times lower for participants treated with canagliflozin compared with placebo (hazard ratio, 0.37; 95% CI: 0.31, 0.43; P < .001). The time difference between 10% of patients in the canagliflozin and placebo groups being initiated on insulin from the beginning of the trial was about 2 years. Time to initiation of other AHAs, including metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists and sulphonylureas, was also delayed for canagliflozin versus placebo (P < .001 for each). Compared with placebo, canagliflozin delayed the need for initiation of other AHAs and de...Continue Reading

References

Aug 26, 2015·Annals of the New York Academy of Sciences·Norm RosenthalKeith Demarest
Apr 29, 2016·Biometrics·Dan-Yu LinMartin Oliver Sailer
Mar 1, 2017·Diabetes, Obesity & Metabolism·Bruce NealUNKNOWN CANVAS Program collaborative group
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
May 10, 2018·Diabetes Care·William T CefaluUNKNOWN Insulin Access and Affordability Working Group
May 24, 2018·BMC Family Practice·Kathy EllisAngus Forbes
Apr 26, 2019·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Nordin Mj Hanssen, Karin Am Jandeleit-Dahm

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01032629
NCT01989754

Software Mentioned

CANVAS

Related Concepts

Related Feeds

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Cleveland Clinic Journal of Medicine
René Rodríguez-Gutiérrez, Gloria Gonzalez-Saldivar
Cleveland Clinic Journal of Medicine
David L Keller
© 2021 Meta ULC. All rights reserved